Skip to main content

Table 1 Hospital Readmission Rates and Average Readmission Costs for Medication-Based Patient Cohorts: 1999–2010. The readmission percentage is found by dividing the number readmitted to the hospital by the total number of patients who experienced an initial diabetes-related hospitalization. Readmission cost is expressed in 2010 U.S. dollars

From: Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes

Patient Cohort

Total number (SE)

Number not readmitted (SE)

Number readmitted (SE)

Readmission percentage

Mean readmission cost (SE)

All Patients

13,537,803 (519,634)

10,959,266 (451,218)

2,578,538 (198,384)

19.1

$8,814 ($580)

All SU Patients a

7,871,912 (368,351)

6,204,869 (326,273)

1,667,043 (153,735)

21.2

$9,204 ($769)

SU (SU monotherapy) b

3,217,089 (235,951)

2,470,510 (194,884)

746,579 (106,554)

23.2

$11,148 ($1,558)

SU+ (other AHA)

4,654,823 (274,495)

3,734,359 (247,494)

920,464 (113,487)

19.8

$7,624 ($412)

All Other Oral AHA Patients a

5,665,891 (291,467)

4,754,397 (256,821)

911,495 (108,690)

16.1

$8,098 ($737)

noSU (monotherapy with non-SU AHA) b

5,488,379 (288,154)

4,606,396 (254,357)

881,984 (107,289)

16.1

$7,673 ($763)

noSU+ (> 1 non-SU AHA)

177,512 (na)

148,001 (na)

29,511 (na)

16.6

$20,772 (na)

  1. SE standard error
  2. na not available due to too low raw cell count
  3. SU sulfonylurea
  4. AHA antihyperglycemic agent
  5. a In a comparison between all SU (SU and SU+) patients and all other oral AHA patients, the relevant p-value for readmission rates was 0.017
  6. b In a comparison between SU patients and noSU monotherapy patients, the relevant p-value for readmission rates was 0.003